New data from Eli Lilly reveal that Omvoh (mirikizumab-mrkz) effectively achieves comprehensive disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease after one year of treatment. These outcomes, observed even in patients with prior biologic treatment failure, are linked to improved quality of life and reduced disease symptoms. Omvoh's multidimensional treatment goals represent a shift toward holistic management of inflammatory bowel disease, addressing symptoms, inflammation, and daily life impact. The findings were presented at UEG Week 2026, with ongoing studies exploring combination therapies and pediatric use.
Eli Lilly And Co (LLY) shares trade at USD 1,229.00 with a 1-day gain of 1.45% as of Oct 15, 2026 18:42 WIB on Pluang. The stock's market cap stands at $1.08 trillion, reflecting its significant presence in the health sector. This positive price movement coincides with the news of Omvoh's promising new data in treating ulcerative colitis and Crohn's disease, highlighting ongoing investor interest in Lilly's innovative therapies.
Sangamo Therapeutics has initiated an auction process for its ST-503 program, a clinical-stage treatment targeting chronic neuropathic pain from small fiber neuropathy, with completion expected in Q4 2026. The program has FDA Fast Track status and sh...
Eli Lilly trades at a premium 24x forward earnings but shows revenue growth of 47.7% year-over-year, far surpassing major pharma peers like Novo Nordisk and AbbVie. The company raised its 2026 revenue guidance twice, aiming for $85B-$87B, driven by s...
Johnson & Johnson's stock dropped 5% after reporting a 95.9% fall in net earnings caused by one-time charges including talc litigation costs, despite raising its full-year sales and adjusted earnings outlook. The company's Innovative Medicine divisio...
AbbVie’s stock trades near $277, close to a $279 price target, driven by strong growth in drugs Skyrizi and Rinvoq, and recent FDA approvals including JUVMO for Parkinson’s. The company’s acquisition of Apogee Therapeutics and raised revenue guidance...
